“This case turns on Dr. Kazempour’s state of mind: Did he submit a deficient BLA that he knew, based on his knowledge and experience, would fail in order to inflate CytoDyn’s stock price, as the indictment alleges? Or did he submit this application in good faith, believing that the FDA would follow its standard procedures, give the BLA a fair chance, and send requests for additional information rather than outright reject the application? Due process demands that the FDA give every applicant a fair, unbiased consideration on the merits.”